Investor News

November 25, 2009 - Director's Dealing

Cyprotex PLC

("Cyprotex" or the "Company")

The Company received notification that Dr Anthony Baxter, Chief Executive Officer of the Company, acquired 120,000 ordinary shares in the Company on 25 November 2009 at a price of 3.45 pence per share. As a result of this purchase, Dr Baxter has an interest in 841,400 ordinary shares in the Company representing approximately 0.47 per cent. of the Company's total voting rights.

For further information:
Cyprotex PLC
Tel: +44 (0) 1625 505 100
John Dootson, Chief Financial Officer
ir@cyprotex.com
www.cyprotex.com

Noble & Company
Tel: +44 (0) 20 7763 2200
John Llewellyn-Lloyd
john.llewellyn-lloyd@noblegp.com
Sam Reynolds
sam.reynolds@noblegp.com
www.noblegp.com

Financial Dynamics
Tel: +44 (0) 20 7831 3113
Ben Brewerton / Ben Atwell / John Dineen
cyprotex@fd.com
www.fd.com